Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy: From the viewpoint of cholesterol metabolism

Circulation Journal

Volumn 75, Issue 10, 2011, Pages 2496-2504

  Okada, Kozo ^a   Kimura, Kazuo ^a   Iwahashi, Noriaki ^a   Endo, Tsutomu ^c   Himeno, Hideo ^d   Fukui, Kazuki ^e   Kobayashi, Shunichi ^f   Shimizu, Makoto ^g   Iwasawa, Yuji ^g   Morita, Yukiko ^h   Wada, Atsushi ⁱ   Shigemasa, Tomohiko ^j   Mochida, Yasuyuki ^k   Shimizu, Tomoaki ^l   Sawada, Reimin ^m   Uchino, Kazuaki ^b   Umemura, Satoshi ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^c Saiseikai Yokohama City Southern Hospital   (Japan)

^d Fujisawa City Hospital   (Japan)

^e Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

^f Yokohama Seamen's Insurance Hospital   (Japan)

^g International Goodwill Hospital   (Japan)

^h SAGAMIHARA NATIONAL HOSPITAL   (Japan)

ⁱ CHIGASAKI MUNICIPAL HOSPITAL   (Japan)

^j International University of Health and Welfare   (Japan)

^k Omori Red Cross Hospital   (Japan)

^l Ashigara Kami Hospital   (Japan)

^m JAPANESE RED CROSS SOCIETY   (Japan)

more..

Author keywords

Cholesterol metabolism; Ezetimibe; Hypercholesterolemia; Lipids; Statin

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; CAMPESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FEMALE; HUMAN; LIPID ABSORPTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 80053070696     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0391     Document Type: Article

References (35)

1. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men. Lancet 1986; 2: 933-936.
2. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-1707.
3. Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa Y; JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circ J 2010; 74: 510-517.
4. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, et al; JELIS Investigators. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 2009; 73: 1283-1290.
5. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
6. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14: 45-50.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 highrisk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
9. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-572.
10. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004; 44: 720-732.
11. Feldman T, Koren M, Insull W Jr, McKenney J, Schrott H, Lewin A, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93: 1481-1486.
12. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44: 467-494.
13. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084-1091.
14. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-2415.
15. Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008; 102: 1489-1494.
16. Tilvis RS, Miettinen TA. Serum plant sterols and their relation to cholesterol absorption. Am J Clin Nutr 1986; 43: 92-97.
17. Miettinen TA, Tilvis RS, Kesaniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990; 131: 20-31.
18. Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988; 29: 1149-1155.
19. Miettinen TA, Ahrens EH Jr, Grundy SM. Quantitative isolation and gas-liquid chromatographic analysis of total dietary and fecal neutral steroids. J Lipid Res 1965; 6: 411-424.
20. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-2134.
21. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebocontrolled trial. Mayo Clin Proc 2004; 79: 620-629.
22. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003; 141: 131-137.
23. Miettinen TA, Strandberg TE, Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: Relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol 2000; 20: 1340-1346.
24. Miettinen TA, Gylling H, Strandberg T, Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study: Finnish 4S investigators. BMJ 1998; 316: 1127-1130.
25. Strandberg TE, Tilvis RS, Pitkala KH, Miettinen TA. Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: A prospective study. J Am Coll Cardiol 2006; 48: 708-714.
26. Nissinen MJ, Miettinen TE, Gylling H, Miettinen TA. Applicability of non-cholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men. Nutr Metab Cardiovasc Dis 2010; 20: 308-316.
27. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587.
28. Davidson MH, Palmisano J, Wilson H, Liss C, Dicklin MR. A multicenter, randomized, double-blind clinical trial comparing the lowdensity lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. Clin Ther 2003; 25: 2738-2753.
29. Gylling H, Miettinen TA. Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. Atherosclerosis 1996; 126: 325-332.
30. Mok HY, von Bergmann K, Grundy SM. Effects of continuous and intermittent feeding on biliary lipid outputs in man: Application for measurements of intestinal absorption of cholesterol and bile acids. J Lipid Res 1979; 20: 389-398.
31. Lakshmanan MR, Nepokroeff CM, Ness GC, Dugan RE, Porter JW. Stimulation by insulin of rat liver -hydroxy-methylglutaryl coenzyme A reductase and cholesterol-synthesizing activities. Biochem Biophys Res Commun 1973; 50: 704-710.
32. Ooi EM, Ng TW, Chan DC, Watts GF. Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetes. Diabetes Res Clin Pract 2009; 85: 310-316.
33. Hoenig MR, Sellke FW. Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy. Atherosclerosis 2010; 211: 260-265.
34. Smahelova A, Hyspler R, Haas T, Ticha A, Blaha V, Zadak Z. Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease. Pharmacol Res 2005; 51: 31-36.
35. Cofan M, Escurriol V, Garcia-Otin AL, Moreno-Iribas C, Larranaga N, Sanchez MJ, et al. Association of plasma markers of cholesterol homeostasis with metabolic syndrome components: A cross-sectional study. Nutr Metab Cardiovasc Dis 2010 May 27 [Epub ahead of print].